Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 158.57M P/E - EPS this Y 12.10% Ern Qtrly Grth -
Income -98.57M Forward P/E -1.62 EPS next Y 14.60% 50D Avg Chg -13.00%
Sales 7M PEG - EPS past 5Y - 200D Avg Chg -55.00%
Dividend N/A Price/Book 0.61 EPS next 5Y - 52W High Chg -80.00%
Recommedations 2.30 Quick Ratio 9.48 Shares Outstanding 72.96M 52W Low Chg 3.00%
Insider Own 14.80% ROA -28.07% Shares Float 52.64M Beta 0.20
Inst Own 54.08% ROE -51.48% Shares Shorted/Prior 865.63K/853.64K Price 2.19
Gross Margin - Profit Margin - Avg. Volume 763,098 Target Price 4.00
Oper. Margin -1,422.01% Earnings Date Nov 13 Volume 168,867 Change 0.00%
About Kezar Life Sciences, Inc.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Kezar Life Sciences, Inc. News
11/13/24 Kezar struck again with second FDA hold
11/12/24 Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
10/28/24 Kezar Life Sciences Announces 1-for-10 Reverse Stock Split
10/18/24 Kezar Life Sciences discontinues lupus nephritis programme after fatalities
10/17/24 Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study
10/17/24 Kezar Life Sciences Rejects Concentra Biosciences Takeover Bid, Adopts Rights Plan
10/17/24 Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan
10/17/24 Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update
10/15/24 What Makes Kezar Life Sciences (KZR) a New Buy Stock
10/10/24 Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal
10/08/24 TANG CAPITAL MANAGEMENT LLC Acquires New Stake in Kezar Life Sciences Inc
10/07/24 FDA Put Brakes On Penny Stock Kezar Life Sciences' Mid-Stage Study For Lead Development Candidate After Patient Deaths
10/07/24 FDA places hold on Kezar Life Sciences’ trial for lupus nephritis treatment
10/04/24 Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis
10/01/24 Kezar Life Sciences suspends subject enrolment in trial of lupus nephritis drug
09/30/24 Kezar Life Sciences Suspends Enrollment, Dosing in Phase 2b Trial of Zetomipzomib in Active Lupus Nephritis Patients
09/30/24 Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients
09/04/24 Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08/14/24 Kezar stalls solid tumour trial to focus on autoimmune disease candidate
08/13/24 Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update
KZR Chatroom

User Image trading_momentum Posted - 1 day ago

$AMIX and $KZR shorts just dropped in webull.

User Image anachartanalyst Posted - 1 week ago

$KZR https://anachart.com/wp-content/uploads/ana_temp/1731600135_soc-img.jpg

User Image fishbowl70 Posted - 2 weeks ago

@ElongMask they also started one yesterday with $KZR using thr same wording https://www.businesswire.com/news/home/20241105464303/en/Glancy-Prongay-Murray-LLP-Announces-Investigation-of-Kezar-Life-Sciences-Inc.-KZR

User Image fishbowl70 Posted - 2 weeks ago

$KZR https://www.businesswire.com/news/home/20241105464303/en/Glancy-Prongay-Murray-LLP-Announces-Investigation-of-Kezar-Life-Sciences-Inc.-KZR

User Image klens Posted - 10/31/24

$KZR Since they didn't take Tang's offer. His team will probably recover their money by shorting.

User Image WallStArb Posted - 10/30/24

@FidoucheiaryGainzzz $KZR essentially just did a poison pill making it unlikely anyone will bother. They only have cash no worthy IP

User Image PenkeTrading Posted - 10/30/24

I found you a Golden Cross on the daily chart of Kezar Life Sciences Inc. $KZR #GoldenCross #NASDAQ

User Image FidoucheiaryGainzzz Posted - 10/30/24

$KZR I'm liking what I see here, let's see a bidding war guys!

User Image StockToligist Posted - 10/30/24

IVDA getting ready for an ultra super nova run over $2.00 $KZR $HCTI $GLYC primed for more multi day runs

User Image SQUEAKSBANDIT Posted - 10/30/24

so they turned down $1.10 cash to reverse split? $KZR might not be the first mistake they have made

User Image tradingcalendar Posted - 10/30/24

$KZR 1-for-10 reverse stock split Shares outstanding reduced to 7.3M from 73M

User Image RollingDollars Posted - 10/30/24

$KZR RS 1/10

User Image Stocksrunner Posted - 10/29/24

🚨 Late-night insights! Tonight’s top trending stocks: $KZR $BK $MBLY $SKX $MCK. Short interest is heating up on $KZR and $MBLY, while $MCK shows confidence with a dip in short positions. Keep an eye on these movers—could be some big plays tomorrow! 👀 https://stocksrunner.com/posts/1315

User Image TheStockBob Posted - 10/29/24

$KZR Does anyone have a theory or knowledge why the stock went up on 9/30 after a trial was cancelled due to deaths? Bizarre. I know Tang took 9.9% but that didn't come out until days later.

User Image Family_Guy_ Posted - 10/29/24

$AUPH $KZR just halted, thats a company Tang submitted an offer for several weeks ago.

User Image Tadeo17 Posted - 10/28/24

$KZR Hi, here is something I thought you might find interesting: - https://uk.investing.com/news/assorted/kezar-life-sciences-announces-110-reverse-share-split-432SI-3756435

User Image pocketmoney Posted - 1 month ago

$KZR

User Image pocketmoney Posted - 1 month ago

$KZR offering rejected

User Image OpenOutcrier Posted - 1 month ago

$KZR (-12.4% pre) Kezar Life Sciences (KZR) Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan - SI https://ooc.bz/l/45030

User Image frontiere Posted - 1 month ago

@lqqkerinsiderDOTcom hey i fully agree on everything you wrote. 👍 poignant re IWM / SMID typical bearish/trough seasonality in Oct-Dec w Jan-February bullishness.👍 With $SPRB Spruce Bio the “multiple shots on goal” are 👍deep neg EV (MCap<<cash) for margin of safety 👍x fully discounted (=0 value assigned) catalyst by YE 👍x comps to recent spikes/turnarounds in cash-rich cigar butts like $KZR Kezar 2x re-rating 0.5 ➔ 1.09, $TIL Instil Bio 9x 9.7 ➔ 84.75, $LBPH Longboard 20x 3 ➔ 60. Long SPRB from much higher since their March blowup (early=wrong) but added here at lows.

User Image Maryam2000 Posted - 1 month ago

$KZR pump this shit

User Image D3fiant Posted - 1 month ago

$KZR gets acquisition proposal from Concentra for 1.10 a share

User Image Maryam2000 Posted - 1 month ago

$KZR fucking shit

User Image joe77w Posted - 1 month ago

$KZR $ALXO $HLVX HLVX May be next take over target, too cheap

User Image SenefAS Posted - 1 month ago

$KZR $MCRB Next rumors or bid will be with Tang soon can we assit to a bidding war 🙃

User Image Maryam2000 Posted - 1 month ago

$KZR

User Image SenefAS Posted - 1 month ago

$MCRB $KZR Tang Capital Management own 2.41M share of Seres, it’s made recently a offer to acquire Kezar. Next it’s Seres ? 🤔 https://www.businesswire.com/news/home/20241010708833/en/Kezar-Confirms-Receipt-of-Unsolicited-Non-Binding-Acquisition-Proposal

User Image DonCorleone77 Posted - 1 month ago

$KZR Kezar Life Sciences receives $1.10 per share acquisition proposal from Concentra Kezar Life Sciences announced that it has received an unsolicited, non-binding proposal from Concentra Biosciences, a Delaware limited liability company, to acquire all of the outstanding shares of common stock of Kezar for cash consideration of $1.10 per share, plus a contingent value right that represents the right to receive 80% of the net proceeds from any out-license or disposition of Kezar's development programs or intellectual property. According to a Schedule 13D filed on October 8, with the SEC disclosing Concentra's proposal, Tang Capital Management is the controlling stockholder of Concentra, and Tang Capital beneficially owns approximately 9.9% of the company's outstanding common stock. Consistent with its fiduciary duties, Kezar's board and management team will evaluate the non-binding proposal to determine the course of action that it believes is in the best interest of the company and all Kezar stockholders and respond appropriately.

User Image themacromindset Posted - 1 month ago

Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal $KZR

User Image OpenOutcrier Posted - 1 month ago

$KZR (+4.7% pre) Kezar Life Sciences (KZR) Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal ($1.10/sh cash) https://ooc.bz/l/44454

Analyst Ratings
HC Wainwright & Co. Neutral Oct 2, 24
HC Wainwright & Co. Buy Aug 14, 24
HC Wainwright & Co. Buy Jul 22, 24
HC Wainwright & Co. Buy May 10, 24
HC Wainwright & Co. Buy Mar 15, 24
HC Wainwright & Co. Buy Dec 4, 23
HC Wainwright & Co. Buy Nov 27, 23
Wells Fargo Equal-Weight Nov 14, 23
HC Wainwright & Co. Buy Oct 12, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Morningside Venture Investment... 10% Owner 10% Owner Jan 23 Sell 6.9 160,000 1,104,000 5,712,993 01/25/23
Morningside Venture Investment... 10% Owner 10% Owner Jan 17 Sell 6.79 6,114 41,514 5,872,993 01/19/23
Kirk Christopher J. President and CSO President and CSO Jun 23 Option 0.90 33,060 29,754 381,484 06/27/22